Oyster Point Pharma, Inc.
OYSTDelisted Jan 3, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001720725
Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.
Holders of 5% or more of OYST
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Oyster Point Pharma, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Oyster Point Pharma, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
20 Schedule 13D and 13G filings on Oyster Point Pharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 2023 | Paradigm Biocapital Advisors LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Jan 13, 2023 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Jan 9, 2023 | New Enterprise Associates 14, L.P. | 13D/AOld format | – | – | – | SEC |
| Jan 5, 2023 | InvOpps IV US, L.P. | 13D/AOld format | – | – | – | SEC |
| Dec 21, 2022 | InvOpps IV US, L.P. | 13D/AOld format | – | – | – | SEC |
| Nov 21, 2022 | New Enterprise Associates 14, L.P. | 13D/AOld format | – | – | – | SEC |
| Jul 18, 2022 | Paradigm Biocapital Advisors LP | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Wellington Management Group LLP | 13G/AOld format | – | – | – | SEC |
| Jan 13, 2022 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Oct 28, 2021 | Point72 Asset Management, L.P. | 13GOld format | – | New | – | SEC |
| Oct 27, 2021 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| May 24, 2021 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 5, 2021 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Mar 1, 2021 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 12, 2021 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2021 | Wellington Management Group LLP | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Oyster Point Pharma, Inc. shares.
No Form 144 notices for Oyster Point Pharma, Inc. are on file.